CRISPR Therapeutics AG (Nasdaq: CRSP)

https://www.crisprtx.com

CRISPR Therapeutics is a leading gene-editing company focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The Company’s multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR/Cas9 patent estate for human therapeutic use was licensed from the Company’s scientific founder Emmanuelle Charpentier, Ph.D., who co-invented the application of CRISPR/Cas9 for gene editing. CRISPR Therapeutics is headquartered in Basel, Switzerland with its R&D operations based in Cambridge, Massachusetts. *

	Start	2013-01-01 established
	Group	CRISPR Therapeutics (Group)
	Industry	CRISPR gene editing technology
	Person	Kulkarni, Samarth (Sam) (CRISPR Therapeutics 201712– promoted CEO before CBO)
	Person 2	Prasad, Raju (CRISPR Therapeutics 202303– CFO before William Blair)

	Region	Basel BS
	Country	Switzerland
	Street	36 Aeschenvorstadt
	City	4051 Basel BS
		Address record changed: 2024-01-05

Basic data	Employees	D: 101 to 500 (2023-12-31)
	Currency	USD
	Annual sales	289,590,000 (revenue, collaboration, consolidated (2019) 2019-12-31)
	Profit	-153,610,000 (2023-12-31)
	Cash	1,693,692,000 (2023-12-31)

		* Document for »About Section«:

		Record changed: 2024-05-30